TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.
Anna Lok, MD
Ranked as the second leading cause of cancer deaths, chronic hepatitis B is the primary cause of liver cancer as an estimated 30 million people world-wide will become newly infected with the disease each year. With the increasing number of available treatments, important questions still remain regarding the HBV population at risk and current practice patterns.
Management of chronic HBV is perceived as a complex paradigm that balances the benefits of long-term suppression of HBV replication with the inconvenience and potential adverse events associated with prolonged, often lifelong, antiviral therapy. Effective monitoring of disease progression and timely initiation of treatment in appropriate patients is essential to help inform interventions and to maximize the long-term outcomes for HBV patients.
TARGET-HBV analyzes patient data from a cohort of HBV patients to answer important questions regarding the HBV patient population and current treatment patterns. The study is designed to characterize the patient population receiving tenofovir alafenamide (among other oral therapies), to inform the safety and effectiveness profile of the therapies and to provide insight into provider decision-making.